Baker Bros. Advisors LP Bicycle Therapeutics PLC Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 9,399,960 shares of BCYC stock, worth $117 Million. This represents 2.28% of its overall portfolio holdings.
Number of Shares
9,399,960
Previous 9,399,960
-0.0%
Holding current value
$117 Million
Previous $190 Million
12.06%
% of portfolio
2.28%
Previous 2.53%
Shares
4 transactions
Others Institutions Holding BCYC
# of Institutions
109Shares Held
41.7MCall Options Held
39.6KPut Options Held
24.6K-
Fcpm Iii Services B.V. Naarden, P73.45MShares$43.1 Million8.16% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.61MShares$32.6 Million0.17% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$28.1 Million0.71% of portfolio
-
Armistice Capital, LLC New York, NY1.96MShares$24.4 Million0.74% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.72MShares$21.5 Million0.0% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $371M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...